PL1723172T3 - Ciekły preparat erytropoetyny - Google Patents

Ciekły preparat erytropoetyny

Info

Publication number: PL1723172T3
Authority: PL; Poland
Prior art keywords: erythropoietin; liquid formulation; epo; formulation; erythropoietin liquid
Prior art date: 2004-03-10

Application number

PL05707735T

Other languages

English (en)

Inventor

Christof Schumann

Jan-Ole Hesse

Original Assignee

Bioceuticals Arzneimittel Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-10

Filing date

2005-03-10

Publication date

2007-12-31

2005-03-10 Application filed by Bioceuticals Arzneimittel Ag filed Critical Bioceuticals Arzneimittel Ag

2007-12-31 Publication of PL1723172T3 publication Critical patent/PL1723172T3/pl

Links

102000003951 Erythropoietin Human genes 0.000 title abstract 4
108090000394 Erythropoietin Proteins 0.000 title abstract 4
229940105423 erythropoietin Drugs 0.000 title abstract 4
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 4
239000012669 liquid formulation Substances 0.000 title 1
230000000694 effects Effects 0.000 abstract 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
230000000567 anti-anemic effect Effects 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
210000001185 bone marrow Anatomy 0.000 abstract 1
239000004202 carbamide Substances 0.000 abstract 1
210000003743 erythrocyte Anatomy 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000003755 preservative agent Substances 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Inks, Pencil-Leads, Or Crayons (AREA)

PL05707735T 2004-03-10 2005-03-10 Ciekły preparat erytropoetyny PL1723172T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE102004011663A DE102004011663B4 (de)	2004-03-10	2004-03-10	Erythropoietin-Flüssigformulierung
EP05707735A EP1723172B1 (de)	2004-03-10	2005-03-10	Erythropoietin-flüssigformulierung
PCT/EP2005/002551 WO2005087804A1 (de)	2004-03-10	2005-03-10	Erythropoietin-flüssigformulierung

Publications (1)

Publication Number	Publication Date
PL1723172T3 true PL1723172T3 (pl)	2007-12-31

Family

ID=34895145

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05707735T PL1723172T3 (pl)	2004-03-10	2005-03-10	Ciekły preparat erytropoetyny

Country Status (13)

Country	Link
US (1)	US7767644B2 (pl)
EP (2)	EP1806361B1 (pl)
JP (1)	JP4887281B2 (pl)
AT (2)	ATE369382T1 (pl)
CA (1)	CA2558985C (pl)
CY (1)	CY1106954T1 (pl)
DE (4)	DE202004020676U1 (pl)
DK (1)	DK1723172T3 (pl)
ES (1)	ES2292103T3 (pl)
PL (1)	PL1723172T3 (pl)
PT (1)	PT1723172E (pl)
SI (1)	SI1723172T1 (pl)
WO (1)	WO2005087804A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN117530912A (zh) *	2008-08-15	2024-02-09	硬木药品公司	适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
CA2770077A1 (en) *	2009-08-06	2011-02-10	Ironwood Pharmaceuticals, Inc.	Formulations comprising linaclotide
US8933030B2 (en)	2010-02-17	2015-01-13	Ironwwod Pharmaceuticals, Inc.	Treatments for gastrointestinal disorders
DK2603232T3 (da)	2010-08-11	2019-12-09	Ironwood Pharmaceuticals Inc	Stabile formuleringer af linaclotid
US9708371B2 (en)	2011-08-17	2017-07-18	Ironwood Pharmaceuticals, Inc.	Treatments for gastrointestinal disorders
AU2012328524B2 (en)	2011-10-28	2017-05-18	Excelse Bio, Inc.	Protein formulations containing amino acids

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6197229A (ja)	1984-10-18	1986-05-15	Chugai Pharmaceut Co Ltd	安定なエリトロポエチン製剤
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
IT1240314B (it)	1989-09-28	1993-12-07	Immunobiology Research Institutes, Inc.	Formulazioni acquose stabilizzate di piccoli peptidi.
US20030162711A1 (en) *	1996-04-24	2003-08-28	Soren Bjorn	Pharmaceutical formulation
TW518219B (en)	1996-04-26	2003-01-21	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
DE19856443A1 (de)	1998-12-08	2000-06-21	Centeon Pharma Gmbh	Stabilisiertes Antithrombin III-Präparat
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
PT1181036E (pt) *	1999-04-09	2008-10-03	Ortho Mcneil Pharm Inc	Composições farmacêuticas de eritropoietina
YU4602A (sh) *	1999-07-22	2005-06-10	Aventis Pharmaceuticals Inc.	Farmaceutske formulacije zaštićene od dejstva mikroorganizama
PL219131B1 (pl) *	2000-05-15	2015-03-31	Hoffmann La Roche	Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie
US20040022792A1 (en) *	2002-06-17	2004-02-05	Ralph Klinke	Method of stabilizing proteins at low pH

2004
- 2004-03-10 DE DE202004020676U patent/DE202004020676U1/de not_active Expired - Lifetime
- 2004-03-10 DE DE102004011663A patent/DE102004011663B4/de not_active Expired - Fee Related
2005
- 2005-03-10 DK DK05707735T patent/DK1723172T3/da active
- 2005-03-10 PT PT05707735T patent/PT1723172E/pt unknown
- 2005-03-10 AT AT05707735T patent/ATE369382T1/de active
- 2005-03-10 CA CA2558985A patent/CA2558985C/en not_active Expired - Lifetime
- 2005-03-10 EP EP07106020A patent/EP1806361B1/de not_active Expired - Lifetime
- 2005-03-10 ES ES05707735T patent/ES2292103T3/es not_active Expired - Lifetime
- 2005-03-10 JP JP2007502297A patent/JP4887281B2/ja not_active Expired - Lifetime
- 2005-03-10 AT AT07106020T patent/ATE481419T1/de active
- 2005-03-10 WO PCT/EP2005/002551 patent/WO2005087804A1/de not_active Ceased
- 2005-03-10 DE DE502005010276T patent/DE502005010276D1/de not_active Expired - Lifetime
- 2005-03-10 PL PL05707735T patent/PL1723172T3/pl unknown
- 2005-03-10 EP EP05707735A patent/EP1723172B1/de not_active Expired - Lifetime
- 2005-03-10 US US10/592,241 patent/US7767644B2/en not_active Expired - Lifetime
- 2005-03-10 SI SI200530045T patent/SI1723172T1/sl unknown
- 2005-03-10 DE DE502005001187T patent/DE502005001187D1/de not_active Expired - Lifetime
2007
- 2007-10-24 CY CY20071101365T patent/CY1106954T1/el unknown

Also Published As

Publication number	Publication date
DE502005010276D1 (de)	2010-10-28
US20080039371A1 (en)	2008-02-14
EP1806361A1 (de)	2007-07-11
DK1723172T3 (da)	2007-12-27
WO2005087804A1 (de)	2005-09-22
JP2007536215A (ja)	2007-12-13
US7767644B2 (en)	2010-08-03
EP1723172A1 (de)	2006-11-22
DE102004011663A1 (de)	2005-09-29
DE202004020676U1 (de)	2005-11-10
ES2292103T3 (es)	2008-03-01
EP1723172B1 (de)	2007-08-08
ATE481419T1 (de)	2010-10-15
CA2558985A1 (en)	2005-09-22
JP4887281B2 (ja)	2012-02-29
DE502005001187D1 (de)	2007-09-20
PT1723172E (pt)	2007-10-29
ATE369382T1 (de)	2007-08-15
CY1106954T1 (el)	2012-09-26
EP1806361B1 (de)	2010-09-15
CA2558985C (en)	2012-09-25
SI1723172T1 (sl)	2007-12-31
DE102004011663B4 (de)	2006-04-27

Publication	Publication Date	Title
WO2000034317A3 (en)	2000-08-17	Method for reducing immunogenicity of proteins
CY1106954T1 (el)	2012-09-26	Υγρο σκευασμα ερυθροποιητινης
ATE292473T1 (de)	2005-04-15	Thymosin beta 4 stimuliert wundheilung
WO2004037861A3 (en)	2004-07-22	Neutralizing antibodies against gdf-8 and uses therefor
WO2001052875A8 (en)	2001-12-06	Vegf-d/vegf-c/vegf peptidomimetic inhibitor
WO2006004736A3 (en)	2007-06-14	Stable liquid and lyophilized formulation of proteins
CA2596597A1 (en)	2006-08-10	Method for stimulation collagen synthesis and/or kgf expression
WO2004073616A3 (en)	2004-11-25	Elastin digest compositions and methods utilizing same
WO2001064738A3 (fr)	2002-09-06	Sequences d"acides amines derivees des proteines humaines reagissant avec l"heparine facilitant le transfert de substances d"interet a l"interieur des cellules et/ou des noyaux cellulaires
WO2001005810A3 (de)	2001-05-17	CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
EP0744408A3 (en)	1997-01-02	Rhesus ob protein and DNA
WO2006069203A3 (en)	2007-02-22	Methods for proteomic profiling using non-natural amino acids
KR20160136342A (ko)	2016-11-29	모발 성장의 억제를 위한 오스테오폰틴 유도체를 포함하는 조성물
DE50012415D1 (de)	2006-05-11	Zubereitungen zur atraumatischen nagelentfernung
ATE493966T1 (de)	2011-01-15	Mittel zur förderung der hautkollagenproduktion
WO1999060989A3 (de)	2000-03-02	Zubereitung zur behandlung der menschlichen haut und der menschlichen haare mit einer speziellen wirkstoffkombination sowie verwendung dieser wirkstoffkombination
DK1165102T3 (da)	2004-06-01	Matrixproteinpræparater til podning i ikke-mineraliseret væv
WO2003082897A3 (en)	2003-12-18	Synthetic active peptide fragments
NO20003888L (no)	2000-10-02	Anti-enzympreparater omfattende etylendiamindiravsyre
WO2004032863A3 (en)	2004-12-09	Oral formulations for proteins and polypeptides
WO2002074921A3 (en)	2004-02-26	Methods for isolating proteins expressed by dendritic cells
WO2001098355A3 (en)	2002-10-03	Cgi-69 compositions and methods of use
JP2001213792A5 (pl)	2007-07-19
WO2002012336A3 (en)	2003-08-14	TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
WO2001032693A3 (de)	2002-06-20	Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz